美国食品药品监督管理局就Apitegromab作为脊髓性肌萎缩症患者治疗药物发出了完整回应信,该决定完全基于在Catalent Indiana LLC填充完成工厂识别出的观察结果。
美国食品药品监督管理局就Apitegromab作为脊髓性肌萎缩症患者治疗药物发出了完整回应信,该决定完全基于在Catalent Indiana LLC填充完成工厂识别出的观察结果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.